Graphene Investments SAS’s Jazz Pharmaceuticals JAZZ Stock Holding History

Graphene Investments SAS’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.47M	Sell	14,400 -2,900	-17%	-$635K	2.02%	21
2026 Q1	$3.27M	Hold	17,300	–	–	2.2%	10
2025 Q4	$2.94M	Sell	17,300 -9,500	-35%	-$1.46M	1.84%	35
2025 Q3	$3.53M	Hold	26,800	–	–	2.23%	10
2025 Q2	$2.84M	Buy	26,800 +6,200	+30%	+$673K	1.85%	36
2025 Q1	$2.56M	Sell	20,600 -3,600	-15%	-$470K	1.87%	37
2024 Q4	$2.98M	Sell	24,200 -2,800	-10%	-$330K	2.06%	20
2024 Q3	$3.01M	Sell	27,000 -4,400	-14%	-$482K	1.93%	35
2024 Q2	$3.35M	Buy	31,400 +5,700	+22%	+$627K	2.11%	15
2024 Q1	$3.09M	Buy	25,700 +3,300	+15%	+$404K	1.87%	35
2023 Q4	$2.76M	Hold	22,400	–	–	1.79%	41
2023 Q3	$2.9M	Buy	+22,400	New	+$2.98M	2.03%	23

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Graphene Investments SAS's JAZZ Position: Q2 2026 in Review

Graphene Investments SAS reduced its Jazz Pharmaceuticals (JAZZ) stake by 17% in Q2 2026, selling an estimated $635K and leaving 14,400 shares worth $3.47M. The position accounts for 2.02% of the portfolio, ranked #21.

Graphene Investments SAS first reported a position in JAZZ in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.53M in Q3 2025. 130 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Graphene Investments SAS held 14,400 shares of Jazz Pharmaceuticals worth $3.47M as of Q2 2026.
Graphene Investments SAS sold 2,900 Jazz Pharmaceuticals shares in Q2 2026, an estimated $635K.
Jazz Pharmaceuticals made up 2.02% of Graphene Investments SAS's portfolio in Q2 2026, its #21 holding.
Graphene Investments SAS first reported a position in Jazz Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Graphene Investments SAS's Jazz Pharmaceuticals position peaked at $3.53M in Q3 2025.
130 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Graphene Investments SAS's 13F filing for Q2 2026, filed 20 Jul 2026.